News | August 12, 2024
Wockhardt Q1 FY25 revenue up 14%
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
The pooled prevalence of GERD in the Indian population is 15.6 %
Enhanced collaboration under the Memorandum of Cooperation (MoC) between India and Japan in medical product regulations
Centhaquine is a resuscitative agent presently indicated for the treatment of hypovolemic shock by DGCI
This new medication eliminates the need for cold storage, making it more accessible and affordable for SCD patients across India
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
Aurobindo's product is already filed with the Drugs Controller General of India (DCGI) and is expected to be approved soon
The booster vaccine can be administered safely to individuals who have received two doses of either Covaxin or Covishield
Dr. Mandaviya urged the stakeholders to capitalize on the current opportunities
Indian government seeks to promote collaboration with stakeholders and harness potential for achieving growth and development of sector
Subscribe To Our Newsletter & Stay Updated
